Overview of the insider transactions
Julie Green, Invivyd, Inc.'s Chief Human Resources Officer, completed the sale of 40,627 shares of the company's common stock on February 17 and 18, 2026, realizing proceeds of approximately $63,350. The two sales were carried out after restricted stock units vested and were intended to cover associated tax obligations.
Transaction specifics
On February 17, Green disposed of 19,663 shares at a weighted average price of $1.5396, with executed trade prices ranging between $1.505 and $1.590. The next day, February 18, she sold 20,964 shares at a weighted average price of $1.5778, with prices in the $1.550 to $1.595 range. These transactions followed an option exercise on February 15 in which Green exercised options for 99,000 shares of Invivyd common stock that stemmed from restricted stock units.
Post-transaction holdings and market context
After settling the option exercise and the recent sales, Green directly holds 107,717 shares of Invivyd common stock. InvestingPro data cited in company reports places Invivyd's market value at $465 million and indicates the stock is trading close to its Fair Value despite a 33% decline year-to-date. At the time of the report, the share price was trading at $1.65 and the stock has delivered a 189% price return over the past six months, according to InvestingPro data.
Company developments and regulatory interaction
In related corporate news, Invivyd received feedback from the U.S. Food and Drug Administration on its planned Phase 3 LIBERTY trial. The study is intended to evaluate the safety and immunologic profile of the company's monoclonal antibody candidate, VYD2311, compared with commercially available mRNA COVID vaccines. The company also plans to assess the safety of administering VYD2311 alongside an mRNA vaccine.
Analyst coverage and upcoming milestones
H.C. Wainwright has reiterated a Buy rating on Invivyd and maintained a $10.00 price target after discussions with the company’s financial executives. The firm highlighted confidence in Invivyd’s near-term value, citing the anticipated Phase 3 topline results for VYD2311 expected in August.
Commercial and educational outreach
Invivyd announced a national educational campaign about antibodies in partnership with Olympic gold medalist Lindsey Vonn. The campaign is scheduled to launch in early spring 2026, with Vonn serving as the spokesperson. The initiative is described as aiming to increase public understanding of antibodies and their role in preventing infectious diseases.
What the record shows
The sequence of events reported - an option exercise on February 15 for 99,000 shares, followed by two sales on February 17 and 18 totaling 40,627 shares to meet tax obligations, and a remaining direct stake of 107,717 shares - is detailed in the transactions disclosed. Market commentary cited InvestingPro valuation and performance metrics, and separate updates covered regulatory feedback, an analyst reiteration, and an upcoming public education campaign.